Evidence map›Paper›PMID 23381004›Full record

ReviewNature reviews. Clinical oncology2013

Latest research and treatment of advanced-stage epithelial ovarian cancer.

Robert L Coleman, Bradley J Monk, Anil K Sood, Thomas J Herzog

Registry-linked trialOpen access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Nature reviews. Clinical oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02567253 (Intraoperative Intraperitoneal Chemoperfusion to Treat Peritoneal Minimal Residual Disease in Stage III Ovarian Cancer), which is not on this map. Cited by 290 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
290citing papers in PubMed, 4 pooled it
61.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02567253 phase2completednot on this mapstarted 2016, after this paper: background citation

Intraoperative Intraperitoneal Chemoperfusion to Treat Peritoneal Minimal Residual Disease in Stage III Ovarian Cancer: A Randomized Phase II Trial

TypeinterventionalSponsorUniversity Hospital, GhentRan2016 to 2021Enrolled56ConditionsOvarian Cancer, Primary Peritoneal CancerArmsCytoreductive surgery, IPEC with Cisplatin (75mg/m²), IPEC with Cisplatin (100mg/m²), Hypertherm IntraPEritoneal Chemotherapy with Cisplatin (75mg/m²), HIPEC with Cisplatin (100mg/m²)
3 · Its place in the literature

Who cites it

290 citing papers in PubMed, 4 syntheses or guidelines pooled it, 496 citations in OpenAlex.

  1. Correlation between progression-free survival and overall survival in patients with ovarian cancer after cytoreductive surgery: a systematic literature review.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2023
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Integrative Development of a TLR8 Agonist for Ovarian Cancer Chemoimmunotherapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017
    Trial
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

230 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Robert L ColemanDepartment of Gynecologic Oncology & Reproductive Medicine, University of Texas, MD Anderson Cancer Center, 1155 Herman Pressler Drive, Houston, TX 77030, USA. rcoleman@ mdanderson.org
Bradley J Monk
Anil K Sood
Thomas J Herzog
Columbia University · USSt. Joseph's Hospital and Medical Center · USThe University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8M
UNIVERSITY OF TEXAS MD ANDERSON SPORE IN OVARIAN CANCERP50CA083639 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BAST, ROBERT C · 1999 to 2015
$33.0M
Targeting the PI3K Signaling Pathway in Endometrial CarcinomaP50CA098258 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BODURKA, DIANE · 2003 to 2020
$32.0M
Texas Center for Cancer NanomedicineU54CA151668 · NCI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI LOGSDON, CRAIG D · 2010 to 2014
$12.4M
Ovarian Cancer: Mechanisms of Neuroendocrine RegulationR01CA109298 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SOOD, ANIL K · 2005 to 2017
$4.5M
Subcellular localization of nanoparticlesRC2GM092599 · NIGMS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI CHIU, WAH, DECUZZI, PAOLO · 2009 to 2010
$3.0M
Nanovectors for Characterization and Destruction of Breast Tumor VasculatureR01CA128797 · NCI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI FERRARI, MAURO · 2007 to 2010
$1.7M
NCI NIH HHS CA109298NCI NIH HHS CA128797NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA083639NCI NIH HHS P50 CA098258NCI NIH HHS R01 CA109298NCI NIH HHS R01 CA128797NCI NIH HHS U54 CA151668NIGMS NIH HHS RC2 GM092599NIGMS NIH HHS RC2GM092599
6 · The paper itself

Abstract

The natural history of ovarian cancer continues to be characterized by late-stage presentation, metastatic bulky disease burden and stagnant mortality statistics, despite prolific drug development. Robust clinical investigation, particularly with modifications to primary treatment surgical goals and adjuvant therapy are increasing median progression-free survival and overall survival, although the cure rates have been affected only modestly. Maintenance therapy holds promise, but studies have yet to identify an agent and/or strategy that can affect survival. Recurrent disease is largely an incurable state; however, current intervention with selected surgery, combination and targeted therapy and investigational protocols are impacting progression-free survival. Ovarian cancer is a diverse and genomically complex disease, which commands global attention. Rational investigation must balance the high rate of discovery with lagging clinical investigation and limited patient resources. Nevertheless, growth in our armamentarium offers unprecedented opportunities for patients suffering with this disease. This Review presents and reviews the contemporary management of the disease spectrum termed epithelial 'ovarian' cancer and describes the direction and early results of clinical investigation.

Indexed as

Biomedical ResearchCarcinoma, Ovarian EpithelialCombined Modality TherapyFemaleHumansNeoplasms, Glandular and EpithelialOvarian Neoplasms

Identifiers

PMID23381004
PMCPMC3786558
OpenAlexW2068854353

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.